


**Product Name** : GDC-2394  
**Cat. No.** : PC-49396  
**CAS No.** : 2238822-07-4  
**Molecular Formula** : C<sub>20</sub>H<sub>25</sub>N<sub>5</sub>O<sub>4</sub>S  
**Molecular Weight** : 431.511  
**Target** : NOD-like Receptor (NLR)  
**Solubility** : 10 mM in DMSO



## Biological Activity

GDC-2394 (GDC-2394) is a potent and selective **NLRP3** inhibitor with IC<sub>50</sub> of 5.4 nM (IL-1 $\beta$  inhibition in PBMCs).

GDC-2394 inhibits NLRP3-induced caspase-1 activity with IC<sub>50</sub> of 51 nM in THP1 cells, but does not inhibit NLR4-dependent inflammasome activation.

GDC-2394 inhibits NLRP3-dependent IL-1 $\beta$  release from mouse bone marrow-derived macrophages (BMDMs) with IC<sub>50</sub> of 63 nM.

GDC-2394 inhibits LPS plus nigericin-induced ASC speck formation in THP-1 cells with IC<sub>50</sub> of 48 nM.

GDC-2394 inhibits production of IL-1 $\beta$  in human and mouse WB in response to LPS priming and activation by ATP, and also LPS priming and activation by MSU crystals, calcium pyrophosphate dehydrate, and cholesterol crystals in HWB and macrophages.

GDC-2394 (25 mg/kg) significantly reduces joint swelling and pain scores, comparable to that achieved by IL-1 $\beta$  blockade, in rodent model of gouty arthritis induced by intra-articular injection of MSU crystals.

## References

Christopher McBride, et al. *J Med Chem.* 2022 Oct 24. doi: 10.1021/acscimedchem.2c01250.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com